Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results
Date:11/11/2010

h and profitability, while positioning China Pharma to benefit from China's unprecedented $124 billion healthcare reform program," said Ms. Li.  "We believe our future success will be defined by our high-quality manufacturing facilities, strong distribution relationships, and commercialization expertise."

Pipeline UpdateAs of September 30, 2010, China Pharma had nine pipeline drugs in different stages of registration process, including three that have passed China State Food and Drug Administration ("SFDA") technical analysis and entered clinical trials.

  • The Company has completed clinical trials of Candesartan, a front-line drug therapy for the treatment of hypertension. The Company has completed all testing procedures and currently awaits final SFDA production approval.
  • The Company continues to receive positive feedback from patients in the clinical trial of Rosuvastatin, a generic form of Crestor. The majority of patients in the clinical trial have completed the treatment cycle and the trial is near completion.
  • The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in the third quarter of 2010.  Phase I of the clinical trials focused on the study of clinical pharmacology as well as the evaluation of safety on the human body, while observing tolerance and pharmacokinetics to provide support for dosage and drug delivery design. Phase II has commenced.

  • Conference CallThe Company will hold a conference call at 8:00 am EST on November 11, 2010 to discuss third quarter 2010 results.  Listeners may access the call by dialing 1-800-659-2056 or 1-617-614-2714 for international callers; access code: 56441223.  A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com.  A replay of the call will be accessible through November 18, 2010 by dialing 1-888-286-8010 or 1-617-80
    '/>"/>

    SOURCE China Pharma Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
    (Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
    (Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
    Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
    ... Decision Resources, one of the world,s leading ... issues, finds that, owing to its superb efficacy, ... major markets, Ironwood/Forest/Almirall/Astellas,s linaclotide will emerge as the ... syndrome (IBS). In 2019, linaclotide will garner blockbuster ...
    ... Calif., Dec. 16, 2010 Catalyst Biosciences, Inc., the ... proteases, today announced the receipt of a $4.0 million ... the collaboration agreement for the development of improved recombinant ... and other bleeding disorders.   "We are ...
    Cached Medicine Technology:For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019 2Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program 2
    (Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
    (Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
    (Date:7/13/2014)... (PRWEB) July 13, 2014 A ... & Schulte LLC to provide consumers with the most ... accompany use of the blood-thinning medication, as well as ... pending in courts around the country. The law firm ... may have suffered from life-threatening internal bleeding and related ...
    (Date:7/13/2014)... July 13, 2014 According to The ... is a comprehensive program that teaches people how to ... neuropathy without medications. This program also provides people ... of peripheral neuropathy , including numbness, prickling, burning, and ... review that this home treatment program can help people ...
    (Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, iFitDress.com, one ... new selection of red evening gowns . What’s more, ... to 56% off. , The company’s senior spokesman states, “We ... shopping on our website is an enjoyable shopping experience. In ... In our online store, low prices do not always mean ...
    Breaking Medicine News(10 mins):Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
    ... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
    ... Molecular Immunologist and his team has found a new virus ... inflammation and autoimmune diseases. The new delivery system acts as ... virus containing the required genes are transferred into the T ... the immune cells they get attracted towards the cancer cell ...
    ... experience 25% less muscle and joint pain in their old ... has also revealed that people who regularly participate in // ... non-runners even though they are more likely to suffer from ... the level of pain in a group of runners and ...
    ... on many issues, however one issue that is likely// to ... poor Pakistani children later this month for heart treatment. ... many more similar gestures and result in a harmony between ... border have failed to deliver in the last 50 years. ...
    ... Trading is responsible for checking the profits and safety ... NHS. They have to monitor that only branded and ... reasonable. ,The Pharmaceutical Price Regulation Scheme [PPRS] ... agreement of the pricing and quality of the drugs ...
    ... Research suggests that the patients of multiple sclerosis (MS) ... at risk from it. ,Although treatment with interferon ... damage in the brains of patients with multiple sclerosis ... called black holes, on magnetic resonance imaging (MRI), treatment ...
    Cached Medicine News:Health News:Surgeons in India to Mend ‘Pakistani Hearts’ by treating 70 Childr 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Patients Of MS Are Not At Risk From The Interferon Treatment 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: